Status:
COMPLETED
Transcranial Photobiomodulation for Executive Function in Bipolar Disorder
Lead Sponsor:
Paolo Cassano
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Transcranial light therapy, or transcranial photobiomodulation (tPBM), is a treatment that stimulates the brain by applying near-infrared light to the forehead. Transcranial light therapy has been fou...
Detailed Description
This study involves a virtual screening visit, 7 in-office visits, and a virtual check-in call with a clinician. Participation will last approximately 3 weeks in total. Participants will attend a bas...
Eligibility Criteria
Inclusion
- Adults between the ages of 18 and 65
- Diagnosis of bipolar disorder
- Currently experiencing symptoms of impulsivity
- Vision normal or corrected to normal with contacts
Exclusion
- Currently in depressive, manic, or mixed episode
- Currently psychotic
- Judged to be at serious and imminent suicidal risk
- Currently in alcohol or substance use disorder (meeting criteria in the past 3 months)
- Unstable medical conditions
- Inability to consent or to complete study procedures
- Failure to meet standard MRI safety requirements (e.g. claustrophobia, non-removable piercings, implanted medical devices, other non-removable metals)
- Changes in medications or use of augmentative devices and other interventions in the 2 weeks prior to the study
- Participation in other clinical research trials that may influence primary outcomes or adherence to the proposed study
- Current pregnancy.
Key Trial Info
Start Date :
August 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 14 2024
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT05408637
Start Date
August 9 2022
End Date
May 14 2024
Last Update
August 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mass General Hospital Navy Yard Building 149
Charlestown, Massachusetts, United States, 02129